Subscribe To
RPTX / Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
RPTX News
By Zacks Investment Research
October 11, 2023
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, comb more_horizontal
By Zacks Investment Research
October 9, 2023
Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks
The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to thi more_horizontal
By Zacks Investment Research
September 20, 2023
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal
By The Motley Fool
August 16, 2023
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
Cathie Wood's ARK Genomic Revolution ETF is a top shareholder of Repare Therapeutics. Wood, along with several Wall Street analysts, hold an overtly b more_horizontal
By Zacks Investment Research
May 9, 2023
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compare more_horizontal
By Zacks Investment Research
May 3, 2023
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%
The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric more_horizontal
By Zacks Investment Research
February 28, 2023
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do t more_horizontal
By Zacks Investment Research
December 2, 2022
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average? more_horizontal